ClinicalTrials.gg
Not yet recruitingNCT07662278rSIFN-coUpdated Jun 23, 2026

rSIFN-co in Combination With Total Neo-adjuvant Therapy in Subjects With Mid-low Locally Advanced Rectal Cancer

A Phase 2 interventional study of Recombinant Super-Compound Interferon (rSIFN-co) and Total Neo-adjuvant therapy in Mid-low Locally Advanced Rectal Cancer, sponsored by Sichuan Huiyang Life Science and Technology Corporation. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Sichuan Huiyang Life Science and Technology Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multi-center, randomized, phase II study, aimed to evaluate the efficacy of investigational product at a dose of 1800 µg/day when given in combination with TNT. There will be two arms included in this study: Arm A (TNT regimen

+ 1800 µg/day of rSIFN-co treatment) and Arm B (TNT regimen only). Subjects will be randomly assigned to any of the two arms in a 2:1 ratio to receive TNT regimen concurrently with rSIFN-co treatment twice a week or TNT regimen only. The efficacy of rSIFN-co when given in combination with Total Neo-adjuvant Therapy (TNT) will be measured by complete response. Where, complete response is defined as subjects with pathological complete response (pCR) or clinical complete response (cCR).

02

Conditions studied

  • Mid-low Locally Advanced Rectal Cancer

Browse trials for

03

In context

Rectal Neoplasms

2,403 studies on the registry are indexed under Rectal Neoplasms; 589 are open to participants now.

This study's planned enrollment of 90 is above the median of 65 across 1,753 interventional studies indexed under Rectal Neoplasms.

Browse Rectal Neoplasms studies →

Lead sponsor

Sichuan Huiyang Life Science and Technology Corporation is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Male and female subjects ≥18 years of age and having ≥ 17 kg/m2. 2.Subjects with or cytologically confirmed mid-low locally advanced rectal cancer, with tumor location within 12 cm from the anal verge, as per UICC classification, and who are scheduled to undergo TNT in the opinion of the investigator 3.Subjects having rectal cancer with pMMR/MSS tumor type and TNM stage: T3, N any, M0; T1-2, N1-2, M0; T4, N any, M0 or locally unresectable or medically inoperable or subjects who are eligible for sphincter sparing surgery.

    4.Subjects with Performance Status 0-2 (Ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours). [As per Appendix A] 5.Subjects with of at least 6 months 6.Subjects willing and able to comply with all study requirements, including study treatment, timing and/or nature of required assessments.

    7.Subjects with normal organ functions prior to enrollment in study:

    1. Blood routine examination

      * WBC: ≥ 4×109/L;

      • content (HB) ≥ 9.0 g/dl (no blood transfusion within 28 days);
      • (ANC) ≥ 1.5 × 109/L;
      • (PLT) ≥ 100 × 109/L.
    2. Biochemical examination * Total (TBIL) ≤ 1.5 × ;

      • and AST ≤ 2.5 × ULN; (CrCl) ≥ 60ml/min using the Cockcroft Gault formula 8.Adequate coagulation function, defined as (INR) and prothrombin time (PT) ≤ 1.5 × ULN; 9.Female subjects with negative serum pregnancy test at screening and negative urine pregnancy test at baseline.

        10.Female subjects of agrees to use a medically acceptable method of throughout the study and for at least 6 months after receiving the final dose.

Acceptable methods of contraception are:

  1. Intrauterine device (IUD) or Intrauterine system (IUS)
  2. Double barrier method of contraception (condom and occlusive cap or condom and spermicidal agent)
  3. Male sterilization (at least 06 months prior to the screening, should be the sole male partner for that subject)
  4. Female sterilization (surgical bilateral oophorectomy) or tubal ligation at least 06 weeks prior to study participation
  5. Total abstinence (partial abstinence is not acceptable). 11.Male subjects with female partners of must agree to use condoms (or any barrier method of contraception) throughout the study and for at least 3 months after receiving the final dose.

Exclusion criteria

Exclusion Criteria:

  • 1.Subjects with known or to study drug or to any known component of study drug formulation.

    2.Subjects who have received treatment with interferon and interferon-like therapy within 30 days prior to screening.

    3.Subjects who had present or prior other than study indication (except cured basal or squamous cell carcinoma, cervical carcinoma).

    4.Subjects who have received radiotherapy prior to screening or had a history of radiotherapy around the pelvic area.

    5.Subjects with known or confirmed severe gastrointestinal inflammation, ileus, or chronic diarrhea (>3 loose stools per day).

    6.Subjects with known or confirmed distant tumor . 7.Subjects with rectal obstruction and significant bleeding. 8.Subjects with history of surgery or trauma: major surgery within 8 weeks prior to screening, such as laparotomy, thoracotomy, organ resection, etc (excluding diagnostic surgical procedures); severe, non-healing wounds, ulcers, or fractures within 8 weeks prior to screening; minor surgery within 7 days prior to screening (excluding diagnostic surgical procedures).

    9.Subjects with other serious conditions that may restrict their participation in the trial (e.g., progressive infection, uncontrolled diabetes or uncontrolled hypertension, serious cardiac dysfunction or angina, active disease, etc.).

    10.Subjects with active infection as determined by positive serology for Virus (HBV), Virus (HCV), or (HIV).

Note: Subjects with controlled HIV, HBV, or HCV infection by antiretroviral therapy will not be excluded.

11.Subjects with other uncontrolled active infections (Grade V5.0 >2), who require treatment with IV antimicrobial therapy, and subjects with active tuberculosis, and subjects undergoing anti syphilis treatment.

12.Subjects with a history of severe skin disease. 13.Subjects with known or confirmed presence of other uncontrollable benign diseases of the lung, liver or kidney and known or confirmed presence of any infection.

14.Subjects with any other medical condition or serious inter-current illness that, in the opinion of the Investigator, may make it undesirable for the subject to participate in the study including but not limited to cirrhosis or psychiatric illness/social situations that would limit adherence to study requirements.

15.Pregnant or lactating women, or female subjects unwilling to use any form of during the study.

16.Subjects with history of alcohol or drug abuse.

Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Arm A (TNT regimen + 1800 µg/day of rSIFN-co treatment)

    Subjects will receive the reconstituted rSIFN-co lyophilized powder via rectum and anus, twice a week, and TNT regimen. In the TNT approach, each subject will receive short-course radiotherapy (RT) (25 Gy in 5 fractions) followed by chemotherapy (6 cycles of CAPEOX), after 2-week rest

    Drug: Recombinant Super-Compound Interferon (rSIFN-co) · Drug: Total Neo-adjuvant therapy

  • Active comparator
    Arm B (TNT regimen only).

    Subject will receive short-course radiotherapy (RT) (25 Gy in 5 fractions) followed by chemotherapy (6 cycles of CAPEOX), after 2-week rest

    Drug: Total Neo-adjuvant therapy

Interventions

  • Subjects will receive the reconstituted rSIFN-co lyophilized powder via rectum and anus, twice a week

  • DrugTotal Neo-adjuvant therapy

    each subject will receive short-course radiotherapy (RT) (25 Gy in 5 fractions) followed by chemotherapy (6 cycles of CAPEOX), after 2-week rest.

06

What researchers measure

Primary outcomes

  1. To evaluate the complete response rate at the end of treatment period

    complete response is defined as the proportion of subjects with pathological complete response (pCR) or clinical complete response (cCR).

    Time frame: at the end of treatment period (approximately at week 25)

Secondary outcomes

  1. To evaluate the proportion of subjects achieving ypT0

    Proportion of subjects achieving ypT0 according to the TNM staging system of the AJCC cancer staging manual, at the end of treatment period

    Time frame: at the end of treatment period (approximately at week 25)

  2. To evaluate the proportion of the subjects with tumor down-staging

    defined as reduction of at least one level in T or N staging between the baseline MRI and histopathological staging, without any evidence of upstaging or disease progression, after treatment with rSIFN-co when given in combination with TNT.

    Time frame: at the end of treatment period (approximately at week 25)

  3. To evaluate the percentage of subjects who are medically inoperable at baseline and who are undergoing surgery after treatment

    Percentage of subjects who are medically inoperable at baseline and who are undergoing surgery after treatment with rSIFN-co when given in combination with TNT

    Time frame: at the end of treatment period (approximately at week 25)

  4. To determine the occurrence of any AEs/SAEs during the study duration

    To determine the occurrence of any AEs/SAEs during the study duration, according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0)

    Time frame: through study completion, an average of 25 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2030, 36 months later.

Of 242 phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 75. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 23, 2026
StartEst.
Jan 2027
Primary completionEst.
Jan 2030
CompletionEst.
Jun 2030
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07662278
Lead sponsor
Sichuan Huiyang Life Science and Technology Corporation
Responsible party
Sponsor
First posted
Jun 23, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jan 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Jun 23, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant Super-compound Interferon

Start the discussion